Loading…
Hosted by BiotechTV · 🇺🇸 US · EN-US · 440 episodes
Established thought leaders with verified media credentials.
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
BiotechTV hosts BiotechTV - News, a science show with 440 episodes published.
Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the t
Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.
Jim Olaghere describes signing up for a gene editing treatment clinical trial for sickle cell disease and how it has enabled him to climb mountains and Bob Coughlin recounts the moment when a therapy became available for
Alexis Borisy recounts the story of Revolution Medicines, which delivered the pancreatic cancer breakthrough this year, and talks about the health of the founder led side of the biotech sector. Mathai Mammen recently too
He describes how science 'keeps you young' because it always based on what you don't know. He urges scientists to stay humble when talking about science to the public because things can change, and he shares stories from
Interviewed by HSBC Innovation Banking's Katherine Andersen, Najat Khan discusses AI, her priorities upon taking the role of CEO at Recursion earlier this year, encouraging employees to speak more than just one language
Moderated by MassBio CEO Kendalle Burlin O'Connel, Kymera Therapeutics CEO Nello Mainolfi, CRISPR Therapeutics CEO Samarth Kulkarni, and Ginkgo Bioworks CEO Jason Kelly discuss their companies' innovations (protein degra
Dr. Zerhouni, the Founder and Chair of ModeX Therapeutics and Former NIH Director, talks about investments in science that started with Vannevar Bush, current day NIH funding, adding a political element to the grant maki
The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the
Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemot
Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR
Philip Astley-Starke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases.
Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning that much work and learning lies ahead, he sees the possibility that such
He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the importance of elevating scientists, what he has found works best for co
He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.
Co-Founder and CEO Serge Saxonov walks us through the platform, which can process up to 800 whole-transcriptome samples per year (1 cm² each) on a single instrument, scaling to thousands of samples per year for targeted
Plus, discussions on key trial readouts outside of obesity: eplontersen, Lp(a), oral IL-23, and milvexian.
He discusses Praxis, Insmed, Ionis, PTC Therapeutics, Rapport, and United Therapeutics.
After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience and how Korro has new momentum with a galNAc delivered approach target
Robert Allen
American rocker · Fort Worth Economic Development Partnership
1 appearance on this show
Peter Hotez
Professor of Pediatrics and Molecular Virology · Baylor College of Medicine
1 appearance on this show
John Cox
The Voice of the Golden Eagles · Roost Booster Painting and Remodeling
1 appearance on this show
John Butler
Board Chair of Atlanta Vietnam Veterans Business Association · Bloomberg Intelligence
1 appearance on this show
Dr. Ian Smith
guest conductor of Bedford Sinfonia and conductor of Bedford Choral Society · National Outdoor Leadership School
1 appearance on this show
Tom Miller
former Deputy District Attorney · Ballard County, Kentucky
1 appearance on this show
Dr. Arun Swaminathan
CEO · Coya Therapeutics
1 appearance on this show
Michael Henderson
CEO · Apogee Therapeutics
1 appearance on this show
Jason Cole
hypermobility specialist · Future Standard
1 appearance on this show
Roger Perlmutter
Eikon Therapeutics
1 appearance on this show
Dr. Mark Goldsmith
Revolution Medicines
1 appearance on this show
Natalie Mount
Cytospire Therapeutics
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch BiotechTV - News, visit https://podcasters.spotify.com/pod/show/biotechtv4 for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
BiotechTV - News is hosted by BiotechTV. The show is categorised under science (life) and has published 440 episodes.
BiotechTV - News has published 440 episodes.
BiotechTV - News regularly covers science, life. It sits in the science category, with a life focus.
BiotechTV - News is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
BiotechTV - News hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of BiotechTV - News average 21 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates BiotechTV - News's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 2 days ago.